Paper30733337
Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
Folk WP and 7 others. J Biol Chem, 2019. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. Papers, record 30733337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30733337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adaptor Proteins, Signal Transducing | Major topic |
| Ataxia Telangiectasia Mutated Proteins | Major topic |
| Cisplatin | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| E2F1 Transcription Factor | Major topic |
| Neoplasms | Major topic |
| Nuclear Proteins | Major topic |
| Transcription, Genetic | Major topic |
| Tumor Suppressor Proteins | Major topic |
| Acid Anhydride Hydrolases | |
| Cell Cycle Proteins | |
| Cell Line, Tumor | |
| DNA Breaks, Double-Stranded | |
| DNA Repair | |
| DNA Repair Enzymes | |
| DNA, Neoplasm | |
| DNA-Binding Proteins | |
| Histones | |
| Humans | |
| MRE11 Homologue Protein | |
| Signal Transduction |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA140379 | NCI NIH HHS | United States | R01CA140379 | PubMed and NIH |
Source NIH RePORTER
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22573178 | RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. | Nucleic Acids Res | 2012 | https://conductscience.org/library/papers/22573178 | PubMed |
| 2 | 12792653 | Yeast histone 2A serine 129 is essential for the efficient repair of checkpoint-blind DNA damage. | EMBO Rep | 2003 | https://conductscience.org/library/papers/12792653 | PubMed |
| 3 | 25512053 | ATM and ATR as therapeutic targets in cancer. | Pharmacol Ther | 2015 | https://conductscience.org/library/papers/25512053 | PubMed |
| 4 | 9733515 | Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. | Science | 1998 | https://conductscience.org/library/papers/9733515 | PubMed |
| 5 | 366407 | The role of cis-platinum in solid-tumor therapy. | N Engl J Med | 1979 | https://conductscience.org/library/papers/366407 | PubMed |
| 6 | 28382507 | Cisplatin nephrotoxicity: a review of the literature. | J Nephrol | 2018 | https://conductscience.org/library/papers/28382507 | PubMed |
| 7 | 16531125 | gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. | DNA Repair (Amst) | 2006 | https://conductscience.org/library/papers/16531125 | PubMed |
| 8 | 12717439 | Chk2 activates E2F-1 in response to DNA damage. | Nat Cell Biol | 2003 | https://conductscience.org/library/papers/12717439 | PubMed |
| 9 | 21447800 | c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. | Sci Signal | 2011 | https://conductscience.org/library/papers/21447800 | PubMed |
| 10 | 18483401 | Activation of the cellular DNA damage response in the absence of DNA lesions. | Science | 2008 | https://conductscience.org/library/papers/18483401 | PubMed |
| 11 | 22469522 | The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. | Biochem Pharmacol | 2012 | https://conductscience.org/library/papers/22469522 | PubMed |
| 12 | 24002223 | Push back to respond better: regulatory inhibition of the DNA double-strand break response. | Nat Rev Mol Cell Biol | 2013 | https://conductscience.org/library/papers/24002223 | PubMed |
| 13 | 8782822 | BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. | Nat Genet | 1996 | https://conductscience.org/library/papers/8782822 | PubMed |
| 14 | 11459832 | Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. | Genes Dev | 2001 | https://conductscience.org/library/papers/11459832 | PubMed |
| 15 | 19808981 | Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. | Mol Cancer Ther | 2009 | https://conductscience.org/library/papers/19808981 | PubMed |
| 16 | 17671430 | Bin1 interacts with and restrains the DNA end-binding protein complex Ku. | Cell Cycle | 2007 | https://conductscience.org/library/papers/17671430 | PubMed |
| 17 | 19005492 | GammaH2AX and cancer. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/19005492 | PubMed |
| 18 | 9395479 | Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. | J Biol Chem | 1997 | https://conductscience.org/library/papers/9395479 | PubMed |
| 19 | 12527885 | ATM is a target for positive regulation by E2F-1. | Oncogene | 2003 | https://conductscience.org/library/papers/12527885 | PubMed |
| 20 | 20177397 | Genomic instability--an evolving hallmark of cancer. | Nat Rev Mol Cell Biol | 2010 | https://conductscience.org/library/papers/20177397 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41250205 | tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/41250205 | PubMed |
| 40808414 | Bridging autophagy and endolysosomal dysfunction: Role of bridging integrator 1 in Alzheimer's disease. | Neural Regen Res | 2026 | https://conductscience.org/library/papers/40808414 | PubMed |
| 40346580 | Tumor cell-intrinsic BIN1 deficiency promotes the immunosuppression and impedes ferroptosis of non-small cell lung cancer via G3BP1-mediated degradation of STAT1. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40346580 | PubMed |
| 40034505 | Lower expression of BIN1's neuronal isoform in vulnerable excitatory neurons increases risk in Alzheimer's disease. | J Alzheimers Dis Rep | 2025 | https://conductscience.org/library/papers/40034505 | PubMed |
| 38934020 | Dementia and metabolic syndrome: a bibliometric analysis. | Front Aging Neurosci | 2024 | https://conductscience.org/library/papers/38934020 | PubMed |
| 37781737 | Glycolytic enzyme PFKFB3 regulates sphingosine 1-phosphate receptor 1 in proangiogenic glomerular endothelial cells under diabetic condition. | Am J Physiol Cell Physiol | 2023 | https://conductscience.org/library/papers/37781737 | PubMed |
| 37239845 | GPR19 Coordinates Multiple Molecular Aspects of Stress Responses Associated with the Aging Process. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37239845 | PubMed |
| 36890396 | BIN1 in cancer: biomarker and therapeutic target. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/36890396 | PubMed |
| 35984905 | Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias. | Blood | 2022 | https://conductscience.org/library/papers/35984905 | PubMed |
| 35526014 | BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia. | Mol Neurodegener | 2022 | https://conductscience.org/library/papers/35526014 | PubMed |
| 35463320 | Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment. | Front Oncol | 2022 | https://conductscience.org/library/papers/35463320 | PubMed |
| 35303867 | Positive regulation of ataxia-telangiectasia-mutated protein (ATM) by E2F transcription Factor 1 (E2F-1) in cisplatin-resistant nasopharyngeal carcinoma cells. | World J Surg Oncol | 2022 | https://conductscience.org/library/papers/35303867 | PubMed |
| 34948122 | New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34948122 | PubMed |
| 34733369 | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 increases cellular proliferation and colony formation capacity in lung cancer via activation of E2F transcription factor 1. | Oncol Lett | 2021 | https://conductscience.org/library/papers/34733369 | PubMed |
| 32601397 | Cellular senescence and Alzheimer disease: the egg and the chicken scenario. | Nat Rev Neurosci | 2020 | https://conductscience.org/library/papers/32601397 | PubMed |
| 32203529 | A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers. | PLoS Biol | 2020 | https://conductscience.org/library/papers/32203529 | PubMed |
| 31981470 | "Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease. | Aging Cell | 2020 | https://conductscience.org/library/papers/31981470 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATM | 472 | PubTator's text mining | https://conductscience.org/library/genes/472 | NCBI Gene |
| BIN1 | 274 | PubTator's text mining | https://conductscience.org/library/genes/274 | NCBI Gene |
| E2F1 | 1869 | PubTator's text mining | https://conductscience.org/library/genes/1869 | NCBI Gene |
| E2F2 | 1870 | PubTator's text mining | https://conductscience.org/library/genes/1870 | NCBI Gene |
| E2F3 | 1871 | PubTator's text mining | https://conductscience.org/library/genes/1871 | NCBI Gene |
| H2AX | 3014 | PubTator's text mining | https://conductscience.org/library/genes/3014 | NCBI Gene |
| MDC1 | 9656 | PubTator's text mining | https://conductscience.org/library/genes/9656 | NCBI Gene |
| MRE11 | 4361 | PubTator's text mining | https://conductscience.org/library/genes/4361 | NCBI Gene |
| NBN | 4683 | PubTator's text mining | https://conductscience.org/library/genes/4683 | NCBI Gene |
| RAD50 | 10111 | PubTator's text mining | https://conductscience.org/library/genes/10111 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30733337
GET https://conductscience.org/api/papers/v1/30733337/references?page=2